Research advances on poor prognostic factors of children with stage 4S neuroblastoma

References:

[1] Wang Z,Sun H,Li K,et al.Prognostic factor analysis of stage 4S neuroblastoma in infant patients:A single center study[J].J Pediatr Surg,2019,54(12):2585-2588.DOI:10.1016/j.jpedsurg.2019.08.031.
[2] Cohn SL,Pearson AD,London WB,et al.The International Neuroblastoma Risk Group (INRG) classification system:an INRG Task Force report[J].J Clin Oncol,2009,27(2):289-297.DOI:10.1200/jco.2008.16.6785.
[3] Raitio A,Rice MJ,Mullassery D,et al.Stage 4S neuroblastoma:what are the outcomes?a systematic review of published studies[J].Eur J Pediatr Surg,2021,31(5):385-389.DOI:10.1055/s-0040-1716836.
[4] Matthay KK.Stage 4S neuroblastoma:what makes it special?[J].J Clin Oncol,1998,16(6):2003-2006.DOI:10.1200/jco.1998.16.6.2003.
[5] Tas ML,Nagtegaal M,Kraal K,et al.Neuroblastoma stage 4S:Tumor regression rate and risk factors of progressive disease[J].Pediatr Blood Cancer,2020,67(4):e28061.DOI:10.1002/pbc.28061.
[6] 蔡元霞,武志祥,王奕,等.CDC5L表达对神经母细胞瘤临床及预后评估的意义[J].临床小儿外科杂志,2019,18(6):472-479.DOI:10.3969/j.issn.1671-6353.2019.06.008. Cai YX,Wu ZX,Wang Y,et al.Expression of CDC5L in neuroblastoma and its clinical and prognostic significance[J].J Clin Ped Sur,2019,18(6):472-479.DOI:10.3969/j.issn.1671-6353.2019.06.008.
[7] Katzenstein HM,Bowman LC,Brodeur GM,et al.Prognostic significance of age,MYCN oncogene amplification,tumor cell ploidy,and histology in 110 infants with stage D (S) neuroblastoma:the pediatric oncology group experience-a pediatric oncology group study[J].J Clin Oncol,1998,16(6):2007-2017.DOI:10.1200/jco.1998.16.6.2007.
[8] Nakazawa A.Biological categories of neuroblastoma based on the international neuroblastoma pathology classification for treatment stratification[J].Pathol Int,2021,71(4):232-244.DOI:10.1111/pin.13085.
[9] Hachitanda Y,Hata J.Stage IVS neuroblastoma:a clinical,histological,and biological analysis of 45 cases[J].Hum Pathol,1996,27(11):1135-1138.DOI:10.1016/s0046-8177(96)90304-4.
[10] De Bernardi B,Di Cataldo A,Garaventa A,et al.Stage 4s neuroblastoma:features,management and outcome of 268 cases from the Italian Neuroblastoma Registry[J].Ital J Pediatr,2019,45(1):8.DOI:10.1186/s13052-018-0599-1.
[11] Kawano A,Hazard FK,Chiu B,et al.Stage 4S Neuroblastoma:Molecular,Histologic,and Immunohistochemical Characteristics and Presence of 2 Distinct Patterns of MYCN Protein Overexpression-A Report From the Children’s Oncology Group[J].Am J Surg Pathol,2021,45(8):1075-1081.DOI:10.1097/pas.0000000000001647.
[12] Pajtler KW,Mahlow E,Odersky A,et al.Neuroblastoma in dialog with its stroma:NTRK1 is a regulator of cellular cross-talk with Schwann cells[J].Oncotarget,2014,5(22):11180-11192.DOI:10.18632/oncotarget.2611.
[13] Huang M,Weiss WA.Neuroblastoma and MYCN[J].Cold Spring Harb Perspect Med,2013,3(10):a014415.DOI:10.1101/cshperspect.a014415.
[14] Ruiz-Pérez MV,Henley AB,Arsenian-Henriksson M.The MYCN Protein in Health and Disease[J].Genes (Basel),2017,8(4):113.DOI:10.3390/genes8040113.
[15] Berbegall AP,Bogen D,P?tschger U,et al.Heterogeneous MYCN amplification in neuroblastoma:a SIOP Europe Neuroblastoma Study[J].Br J Cancer,2018,118(11):1502-1512.DOI:10.1038/s41416-018-0098-6.
[16] Yong MH,Hwang WS,Knight LA,et al.Comparing histopathological classification with MYCN,1p36 and 17q status detected by fluorescence in situ hybridization from 14 untreated primary neuroblastomas in Singapore[J].Singapore Med J,2009,50(11):1090-1094.
[17] Iehara T,Hiyama E,Tajiri T,et al.Is the prognosis of stage 4s neuroblastoma in patients 12 months of age and older really excellent?[J].Eur J Cancer,2012,48(11):1707-1712.DOI:10.1016/j.ejca.2012.01.010.
[18] Twist CJ,Naranjo A,Schmidt ML,et al.Defining Risk Factors for Chemotherapeutic Intervention in Infants With Stage 4S Neuroblastoma:A Report From Children’s Oncology Group Study ANBL0531[J].J Clin Oncol,2019,37(2):115-124.DOI:10.1200/jco.18.00419.
[19] Swift CC,Eklund MJ,Kraveka JM,et al.Updates in Diagnosis,Management,and Treatment of Neuroblastoma[J].Radiographics,2018,38(2):566-580.DOI:10.1148/rg.2018170132.
[20] Bowman LC,Castleberry RP,Cantor A,et al.Genetic staging of unresectable or metastatic neuroblastoma in infants:a Pediatric Oncology Group study[J].J Natl Cancer Inst,1997,89(5):373-380.DOI:10.1093/jnci/89.5.373.
[21] Mlakar V,Jurkovic Mlakar S,Lopez G,et al.11q deletion in neuroblastoma:a review of biological and clinical implications[J].Mol Cancer,2017,16(1):114.DOI:10.1186/s12943-017-0686-8.
[22] Spitz R,Hero B,Ernestus K,et al.Deletions in chromosome arms 3p and 11q are new prognostic markers in localized and 4s neuroblastoma[J].Clin Cancer Res,2003,9(1):52-58.
[23] Juan Ribelles A,Barberá S,Yá?ez Y,et al.Clinical features of neuroblastoma with 11q deletion:an increase in relapse probabilities in localized and 4S stages[J].Sci Rep,2019,9(1):13806.DOI:10.1038/s41598-019-50327-5.
[24] Coronado E,Ya?ez Y,Vidal E,et al.Intratumoral immunosuppression profiles in 11q-deleted neuroblastomas provide new potential therapeutic targets[J].Mol Oncol,2021,15(2):364-380.DOI:10.1002/1878-0261.12868.
[25] Buckley PG,Alcock L,Bryan K,et al.Chromosomal and microRNA expression patterns reveal biologically distinct subgroups of 11q-neuroblastoma[J].Clin Cancer Res,2010,16(11):2971-2978.DOI:10.1158/1078-0432.Ccr-09-3215.
[26] Komotar RJ,Otten ML,Starke RM,et al.Chromosome 1p and 11q deletions and outcome in neuroblastoma-a critical review[J].Clin Med Oncol,2008,2:419-420.DOI:10.4137/cmo.s391.
[27] Costa RA,Seuánez HN.Investigation of major genetic alterations in neuroblastoma[J].Mol Biol Rep,2018,45(3):287-295.DOI:10.1007/s11033-018-4161-4.
[28] Taggart DR,London WB,Schmidt ML,et al.Prognostic value of the stage 4S metastatic pattern and tumor biology in patients with metastatic neuroblastoma diagnosed between birth and 18 months of age[J].J Clin Oncol,2011,29(33):4358-4364.DOI:10.1200/jco.2011.35.9570.
[29] Henrich KO,Schwab M,Westermann F.1p36 tumor suppression-a matter of dosage?[J].Cancer Res,2012,72(23):6079-6088.DOI:10.1158/0008-5472.Can-12-2230.
[30] García-López J,Wallace K,Otero JH,et al.Large 1p36 deletions affecting Arid1a locus facilitate mycn-driven oncogenesis in neuroblastoma[J].Cell Rep,2020,30(2):454-464.e5.DOI:10.1016/j.celrep.2019.12.048.
[31] Kuzyk A,Booth S,Righolt C,et al.MYCN overexpression is associated with unbalanced copy number gain,altered nuclear location,and overexpression of chromosome arm 17q genes in neuroblastoma tumors and cell lines[J].Genes Chromosomes Cancer,2015,54(10):616-628.DOI:10.1002/gcc.22273.
[32] Parodi S,Sorrentino S,Cataldo AD,et al.Metastatic progression in infants diagnosed with stage 4S neuroblastoma.A study of the Italian Neuroblastoma Registry[J].Pediatr Blood Cancer,2021,68(5):e28904.DOI:10.1002/pbc.28904.
[33] van Noesel MM.Neuroblastoma stage 4S:a multifocal stem-cell disease of the developing neural crest[J].Lancet Oncol,2012,13(3):229-230.DOI:10.1016/s1470-2045(12)70012-8.
[34] Schumacher-Kuckelkorn R,Volland R,Gradehandt A,et al.Lack of immunocytological GD2 expression on neuroblastoma cells in bone marrow at diagnosis,during treatment,and at recurrence[J].Pediatr Blood Cancer,2017,64(1):46-56.DOI:10.1002/pbc.26184.
[35] Sorrentino S,Rosanda C,Parodi S,et al.Cyto-morphologic evaluation of bone marrow in infants with disseminated neuroblastoma[J].J Pediatr Hematol Oncol,2012,34(2):154-158.DOI:10.1097/MPH.0b013e31821d80be.
[36] French AE,Irwin MS,Navarro OM,et al.Long-term hepatic outcomes in survivors of stage 4S and 4 neuroblastoma in infancy[J].Pediatr Blood Cancer,2012,58(2):283-288.DOI:10.1002/pbc.23077.
[37] Ahmed AA,Zhang L,Reddivalla N,et al.Neuroblastoma in children:Update on clinicopathologic and genetic prognostic factors[J].Pediatr Hematol Oncol,2017,34(3):165-185.DOI:10.1080/08880018.2017.1330375.
[38] Avanzini S,Buffoni I,Gigliotti AR,et al.Resection of primary tumor in stage 4S neuroblastoma:a second study by the Italian Neuroblastoma Group[J].Pediatr Surg Int,2021,37(1):37-47.DOI:10.1007/s00383-020-04766-1.